Living with melanoma: a study protocol for the design and participatory development of a survivorship care programme for people with metastatic melanoma Authors: Madlen Hörold, Karl Philipp Drewitz, Sebastian Haferkamp, Jochen Schmitt, Friedegund Meier, Lea Pöschmann, Maike Bergmann, Sophia Lehr, Christian Apfelbacher Published: 2026 ABSTRACT AbstractBackgroundThe growing number of people living with and beyond melanoma report unmet needs in survivorship care. To optimize melanoma survivorship care, it is critical to consider not only the perspectives of survivors of melanoma and their relatives, but also those of oncology healthcare professionals. The aim of this study is to develop an innovative survivorship care programme for people living with and beyond metastatic melanoma.MethodsThe study follows the UK Medical Research Council framework and the intervention mapping approach. It also integrates the perspectives of all relevant stakeholders, from survivors of melanoma and their families to healthcare professionals. The development process (phase A) includes a scoping review and a qualitative study with interviews and focus groups. Stakeholder knowledge will be integrated through a participatory process involving patients, relatives, physicians, psycho-oncologists, nurses, epidemiologists and health services researchers.DiscussionUsing different methodological approaches, we hope to gain insight into the needs of survivors of melanoma and develop a theory- and evidence-based survivorship care programme. The planned study will provide a patient-centred intervention to improve health-related outcomes for people with metastatic melanoma in general and to promote health literacy and quality of life for those affected. The subsequent feasibility and pilot study, including a structure and process evaluation (phase B), will provide an initial opportunity to determine the feasibility of a randomized controlled trial and of the survivorship care programme itself, in preparation for further effectiveness studies.Protocol registrationWe set up an OSF project (https://doi.org/10.17605/OSF.IO/DV7MH) for the LeMela project. In addition, we have pre-registered a short protocol at OSF (https://doi.org/10.17605/OSF.IO/QVRXD). A growing number of people living with and beyond melanoma report having unmet survivorship care needs. A growing number of people living with and beyond melanoma report having unmet survivorship care needs. Little is known about how healthcare professionals should provide a survivorship care programme (SCP) for people living with and beyond metastatic melanoma. Little is known about how healthcare professionals should provide a survivorship care programme (SCP) for people living with and beyond metastatic melanoma. Until now, there has been no structured, individualized SCP for long-term survivors of melanoma in Germany. Until now, there has been no structured, individualized SCP for long-term survivors of melanoma in Germany. Design and participatory development of an SCP for people living with and beyond metastatic melanoma. Design and participatory development of an SCP for people living with and beyond metastatic melanoma. In 2020, about 57 000 people worldwide died from melanoma, with large geographical differences in incidence across nations and global regions.1 The incidence of melanoma continues to increase worldwide.2 According to the Robert Koch Institute, approximately 25 448 people (12 222 women and 13 226 men) were diagnosed with malignant melanoma in Germany in 2022, with a nearly equal sex distribution.3 The 10-year prevalence of malignant melanoma in Germany is approximately 189 000 cases.3 The development of modern therapeutic strategies has improved the prognosis4 and overall survival in recent years.5 Targeted therapy with BRAF/MEK inhibitors and immunotherapy with checkpoint inhibitors have significantly prolonged overall survival. According to the CheckMate 067 trial, the 10-year melanoma-specific survival rate for patients who received combined immunotherapy was 52%.6 This encouraging progress has led to a steady increase in the number of people living with and beyond melanoma long term. The term ‘survivors’ refers to people who are living with and beyond cancer. This includes those who are considered ­disease-free after completing treatment; those receiving further therapy to reduce the risk of recurrence; and those with well-­controlled disease and mild symptoms, who are being treated so they can live with cancer as a chronic condition.7 A widely accepted classification distinguishes between the following stages of survival: early (acute), intermediate and long-term (≥5 years after completing acute treatment).8 Long-term survivors of melanoma often experience significant physical and psychological symptoms, such as depression and anxiety, as well as social distress resulting from the disease and its treatment, including adverse events.9–11 In addition, they face challenges in planning their lives, returning to work or (re)building social relationships.12 Furthermore, people living with and beyond melanoma long term have a high need for psychological or even psychiatric care.13 Health literacy is often low.14 However, the exact factors influencing health-related quality of life and health literacy in people living with and beyond melanoma, as well as how to address these factors, are not fully understood.15 There is agreement that programmes for people living with and beyond melanoma long term should be initiated during the acute phase of treatment.16,17 A survivorship care programme (SCP) is defined as care provided to survivors of cancer that focuses on preventing and detecting treatable cancers and long-term effects, and improving health-related quality of life.8 A central component of SCPs is the survivorship care plan, which aims to inform patients about their disease, treatment and potential effects, and improve coordination of care.18 In 2016 the Clinical Oncology Society of Australia published a position statement on the critical components of cancer survivorship care in Australia.19 In 2022, Lai-Kwon et al. assessed the feasibility, acceptability and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for people with metastatic melanoma.20 However, specific and individualized counselling and treatment for people living with and beyond melanoma long term following a diagnosis of metastatic melanoma, in combination with or beyond medical follow-ups, is nevertheless often an ‘unmet need’.12,18,21 Overall, little is known about how healthcare professionals (HCPs) should provide SCPs to people living with and beyond melanoma.18 Kamminga et al. state that the implementation and effectiveness of survivorship care is currently suboptimal and may benefit from tailoring its content to the needs of key stakeholders. Efforts should focus on providing psychosocial support, including assistance with returning to work, preferably including the patient’s close family12 from the time of diagnosis. A single point of contact and a personalized SCP could be of additional benefit to people living with and beyond melanoma long term.12,18,21 Promoting health literacy is also important in this context.22 Currently, clinics in Germany offer rehabilitation programmes with a psycho-oncological focus that include ­exercise therapy, relaxation therapy, sociomedical support for re­integration and aftercare programmes. However, the process and content of cancer rehabilitation in those facilities can vary from person to person. Comprehensive Cancer Centres (CCCs)23 in Germany play a crucial role in supporting people living with and beyond melanoma long term by providing medical, psychosocial and rehabilitative care to enhance their quality of life. In addition, regional survivorship programmes have been established. For example, the Bayerisches Zentrum für Krebsforschung (BZKF) in Germany is a collaborative network of six Bavarian university hospitals that supports cancer survivorship by providing patient information, facilitating shared decision-making and conducting applied research.24 The BZKF is also distinguished by its steadily growing patient expert pool [Patient-Experten-Pool (PEP)] which includes survivors of cancer and their families. The PEP supports research projects and provides patient perspectives during the design and planning stages of clinical trials, ensuring that studies address relevant patient needs and concerns. The University Medical Center Hamburg-Eppendorf has established a ‘Life after Cancer’25 consultation for people diagnosed with cancer. In addition, the Cancer Information Service26 and patient support groups such as ‘Melanom Info Deutschland’27 offer information on living with and beyond cancer. Furthermore, the German Cancer Research Center has started working on a support programme for people living with and beyond melanoma long term aged ≥65 years.28 Currently, there is no structured, individualized SCP in Germany that standardizes and summarizes the various existing approaches to meet the specific needs of long-term survivors of melanoma. Therefore, the overall aim of our LeMela (‘Living with Melanoma’) project is to develop, pilot test and evaluate an SCP for people living with and beyond metastatic melanoma. To achieve this, we have defined the following objectives for the SCP development (phase A): Identify the challenges of survivorship and their underlying causes following treatment for metastatic melanoma Identify the challenges of survivorship and their underlying causes following treatment for metastatic melanoma Define the programme objectives and develop a matrix of change Define the programme objectives and develop a matrix of change Select the most appropriate intervention and strategies to address identified challenges Select the most appropriate intervention and strategies to address identified challenges Design and organize an SCP for metastatic melanoma Design and organize an SCP for metastatic melanoma Acceptance and implementation planning Acceptance and implementation planning Evaluation planning Evaluation planning Materials and methods Our study protocol is based on GUIDED, a guideline for reporting for intervention development studies.29 We set up an OSF project (https://doi.org/10.17605/OSF.IO/DV7MH) for the LeMela project. In addition, we have decided to pre-register a short protocol at OSF (https://doi.org/10.17605/OSF.IO/QVRXD). Study setting, roles and responsibilities The LeMela project is led by the Institute for Social Medicine and Health Systems Research at Otto von Guericke University Magdeburg, Germany. The project will be conducted in close cooperation with the Department of Dermatology and Venereology, University Hospital Halle, the Skin Cancer Center at the National Center for Tumor Diseases (NCT/UCC), University Hospital and Medical Faculty Carl Gustav Carus Dresden and the Centre for Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus Dresden, Germany. The LeMela project, which started in December 2024, will be conducted until May 2028. The following bodies are responsible for the management of the project: (i) executive team, project leaders of the four work packages (WPs), (ii) management team, all academic staff (research assistants and study physicians), (iii) patient and relatives’ team, and (iv) a project advisory board. Study design LeMela is a mixed-methods study conducted in two phases. Phase A involved the design and participatory development of an SCP for people living with and beyond metastatic melanoma (WPs 1 and 2), referred to below as ‘people living with and beyond melanoma’. Phase B will comprise a feasibility and pilot study at two German university hospitals. We will evaluate the feasibility of a pragmatic randomized controlled trial comparing the SCP intervention with usual care and the feasibility of the SCP itself (WPs 3 and 4) (Figure 1). A separate study protocol will be published for phase B. Study design and schedule. LeMela, Living with Melanoma; SCP, survivorship care programme; WP, work package. The LeMela project is guided by the UK Medical Research Council (MRC) framework for the development and evaluation of complex interventions,30 the throughput model31,32 and the Intervention Mapping (IM) approach.33 The MRC framework defines four phases: ‘development or identification of an intervention, assessment of feasibility of the intervention and evaluation design, evaluation of the intervention, and impactful implementation’.30 However, these phases are not necessarily sequential.30 The IM protocol follows the philosophy of participatory research and is based on six steps.33,34 We will use the IM protocol to develop an intervention that focuses on the needs of long-term survivors of melanoma, as well as theory- and evidence-based practices.33,35 The throughput model and the UCSF symptom management theory are intended as the theoretical framework for the SCP to be developed. The throughput model describes how input factors (e.g. the resources available to people living with and beyond melanoma, their relatives and healthcare providers; organizational and system structures; and health policy context factors) influence throughput (e.g. organizational, diagnostic, and therapeutic structures and processes), which in turn influences output (e.g. directly provided healthcare services) and outcome.32 The symptom management theory further describes symptom management as a multidimensional process that should be relevant to all populations experiencing illness-related symptoms. Effective symptom management requires considering each component of the model: experiencing symptoms, management strategies and outcomes.36 In the following sections, we will only refer to phase A, ‘Design and participatory development’. Work package 1: conceptualization In WP 1, which started in March 2025, we will conceptualize and discuss the challenges of melanoma survivorship and their causes within the context of treatment. We will systematically map the available literature on key components of survivorship care for individuals living with and beyond melanoma that address physical, psychological and psychosocial needs, including emotional support, communication, coping mechanisms, and challenges to physical and mental health. The scoping review was conducted in accordance to the methodological guidance for scoping reviews provided by the Joanna Briggs Institute (JBI)37 and the framework of Levac et al.38 Our search string was developed using the PCC (population, concept, context) framework (Table 1), as outlined in the JBI framework for scoping reviews. Our search strategy covered bibliographic and scientific databases, including MEDLINE®, Cochrane Reviews and Science Citation Index & Social Sciences Citation Index (Web of Science). In addition, we conducted a manual search of the reference lists of the systematic reviews that we screened. In order to complete the scoping review within the project timeframe, we limited the search to publications published from January 2015 up to March 2025. Title and abstract screening was based on the predefined research question. Two researchers independently screened the titles and abstracts, applying defined inclusion and exclusion criteria (Table 1); they made the final decision on inclusion in the full-text screening stage. Next, the full texts were checked for inclusion or exclusion. Any disagreements were resolved through discussion by the review team. Table 1Population, concept, context and type of evidence: inclusion and exclusion criteria Population People living with and beyond melanoma aged >18 years, and their relatives At least 80% of participants had melanoma AND/OR specific subgroup analysis of patients with melanoma Healthcare professionals who care for people living with and beyond melanoma, including physicians from dermatology, haematology/oncology, palliative medicine, psychologists, psycho-oncologists, therapists (physiotherapy/occupational therapy), nurses and medical assistants Concept Survivorship care Interventions on survivorship care that address physical, psychological and psychosocial need, including emotional support, communication, coping mechanisms, and challenges to physical and mental health Context Studies in clinical and community settings; studies that are conducted only in the context of palliative care units or only focus on pharmacological interventions will be excluded Studies published between January 2015 and March 2025 Studies published in English or German Type of evidence Qualitative and quantitative studies Reviews We will exclude study protocols, editorials, commentaries, books or book chapters, guidelines, position statements, conference proceedings, abstracts and dissertations Population, concept, context and type of evidence: inclusion and exclusion criteria People living with and beyond melanoma aged >18 years, and their relatives People living with and beyond melanoma aged >18 years, and their relatives At least 80% of participants had melanoma AND/OR specific subgroup analysis of patients with melanoma At least 80% of participants had melanoma AND/OR specific subgroup analysis of patients with melanoma Healthcare professionals who care for people living with and beyond melanoma, including physicians from dermatology, haematology/oncology, palliative medicine, psychologists, psycho-oncologists, therapists (physiotherapy/occupational therapy), nurses and medical assistants Healthcare professionals who care for people living with and beyond melanoma, including physicians from dermatology, haematology/oncology, palliative medicine, psychologists, psycho-oncologists, therapists (physiotherapy/occupational therapy), nurses and medical assistants Survivorship care Survivorship care Interventions on survivorship care that address physical, psychological and psychosocial need, including emotional support, communication, coping mechanisms, and challenges to physical and mental health Interventions on survivorship care that address physical, psychological and psychosocial need, including emotional support, communication, coping mechanisms, and challenges to physical and mental health Studies in clinical and community settings; studies that are conducted only in the context of palliative care units or only focus on pharmacological interventions will be excluded Studies in clinical and community settings; studies that are conducted only in the context of palliative care units or only focus on pharmacological interventions will be excluded Studies published between January 2015 and March 2025 Studies published between January 2015 and March 2025 Studies published in English or German Studies published in English or German Qualitative and quantitative studies Qualitative and quantitative studies Reviews Reviews We will exclude study protocols, editorials, commentaries, books or book chapters, guidelines, position statements, conference proceedings, abstracts and dissertations We will exclude study protocols, editorials, commentaries, books or book chapters, guidelines, position statements, conference proceedings, abstracts and dissertations At least two people extracted data from the included articles independently and resolved any discrepancies through a verification process. We used a specially designed extraction form that prioritized evidence for intervention development. Rayyan was used to manage the data (https://www.rayyan.ai/). Findings were synthesized and categorized narratively and quantitatively. Our findings included information on study type, sample size, data collection methods, participant demographics, and the key concepts of survivorship care and associated outcomes. Reporting will follow the PRISMA-ScR guidelines. We will now discuss the results with support of relevant stakeholders from dermato-oncology [e.g. representatives of the Arbeitsgemeinschaft Dermatologische Onkologie (ADO)], epidemiology and health services research. The aim is to integrate the existing structures of the respective university hospital (e.g. social services, nutrition counselling, psycho-oncology and exercise therapy) in the SCP to be developed. Our findings will be translated into a model of change based on the IM protocol.33,39 Following this, the scientific study team will develop a first draft of the intervention, as well as the implementation and evaluation plan, in close collaboration with our patient and relatives’ team and the project advisory board. In addition, the results of WP1 will serve as the basis for the participatory further development of the intervention. Work package 2: participatory development WP 2 is methodologically based on a qualitative40 and a participatory research approach.41 We will also use creativity and innovation strategies, such as design thinking42 and the Walt Disney method.43 Interviews and focus groups will be conducted with individuals living with and beyond melanoma, their relatives and HCPs to discuss and further develop the draft of the SCP developed in WP 1. Sample and eligibility criteria In WP 2, we will focus on three different target groups: (i) people who have been diagnosed with melanoma and are either undergoing or have undergone initial tumour therapy, as well as (ii) their relatives and (iii) relevant HCPs (Table 2). By including people with stage IIB/C melanoma who are at high risk of disease progression, we aim to get as many different perspectives (‘difference information’) as possible. We believe that this group of patients could potentially provide important insights into the specific follow-up needs associated with possible disease progression. In other words, the needs of this group could reveal differences or similarities compared with those with stage III or IV melanoma. This could provide insight into whether certain needs depend on the stage of the disease, and whether patients with melanoma, with or without metastases, require specific SCPs. Overall, this approach seems to be valuable for supporting the development of an evidence-based and patient-centred SCP. However, to ensure that the focus of the project remains on the originally defined target group, the proportion of participants with stage IIB/C melanoma will be limited to a maximum of 20%. Table 2Work package 2: inclusion and exclusion criteriaInclusion criteriaExclusion criteria People with stage IIB/C, III or IV melanoma during and after initial tumor ­therapy in Germany People with stage 0, IA, IB and IIA melanoma during and after initial tumor therapy Relatives of people with stage IIB/C, III or IV melanoma Relatives of people with stage 0, IA, IB and IIA melanoma Healthcare professionals (HCPs) who care for people living with and beyond melanoma, including: HCPs who do not care for people living with and beyond melanoma -Physicians from dermatology, haematology/oncology and palliative medicine -Therapists: physiotherapy/occupational therapy -Social service -Nurses and medical assistants Living in Germany Place of residence outside Germany Written consent form No written consent Work package 2: inclusion and exclusion criteria Data collection We plan to collect baseline and follow-up data. Based on the draft concept for the SCP developed in WP 1, we will ask about the need for an SCP, the timing of its initiation, its specific components, the expectations of its use, and the opportunities and challenges of its practical implementation and evaluation (Table 3). Table 3Themes for data collectionBaseline themesFollow-up themes: 6 months after baseline(i) Challenges of people living with and beyond melanoma (stage IIB/C, III or IV) and their causes after treatment(i) Organization of the SCP LeMela(ii) Aims of the SCP LeMela(ii) Acceptance and implementation planning(iii) Selection of intervention methods and strategies(iii) Evaluation planningLeMela, Living with Melanoma; SCP, survivorship care programme. Themes for data collection LeMela, Living with Melanoma; SCP, survivorship care programme. Where possible, the participants and our patient and relatives’ team will be actively involved in the research process; they and the academic researchers will interact and advise each other. The aim is to facilitate an iterative discussion process that will lead to a consensus on the SCP concept based on a broad foundation of ideas, perspectives and experiences. Using the design thinking approach42 and Walt Disney method,43 the process will create discursive spaces for problems and solutions related to the SCP. Interviews and focus group discussions will be conducted in person, by telephone or via privacy-compliant video conferencing systems (e.g. Webex and Zoom). Recruitment and sample size Our recruitment process began at the end of March 2025. To access the field, we used personal and professional contacts in Magdeburg, Dresden and Regensburg, Germany. In addition, we used publicly accessible addresses of HCPs and patient support groups, as well as social media (e.g. LinkedIn), notices and flyers in oncological outpatient clinics and skin cancer centres, and snowball sampling to recruit participants. The size and composition of the sample were not finalized in the early phase of the research project. Our considerations are based on the Information Power concept, which is defined by the following five dimensions: Aim, Specificity, Theory, Dialogue and Analysis.44 The research question is relatively narrow and addresses a specific target group. A structured qualitative content analysis approach was chosen for the analysis.45 Therefore, we plan to conduct 6–10 focus group discussions, each with 5–10 participants, as well as 5–10 interviews with people diagnosed with stage IIB/C, III or IV melanoma, their relatives and HCPs. Based on these five dimensions, the study team regularly considered whether collecting more data would yield new insights. Data collection will cease if the existing categories remain unchanged or are confirmed over three consecutive data collections. The data collection process is ongoing. Patient and community involvement This participatory approach ensures that the research questions, methodology and data collection methods are relevant, and respect and meet the specific needs and priorities of the group being studied. Throughout the project, we will continue to involve our patient and relatives’ team and our advisory board; for example, we discussed the interview guide with the patient and relatives’ team before starting data collection. Data management We invite potential participants to participate in interviews or focus groups, provide them with detailed information about the study, and ask them to sign a consent form. We temporarily store their personal contact information at our coordinating research institute, ensuring that only our authorized project personnel have access to it. Signed consent forms are securely sent to a trusted third party, while participants keep a copy for their records. Before data collection begins, we again brief participants on data security. We digitally record all interviews and focus group discussions and follow-up with a postscript and a short socio­demographic questionnaire, both linked to the participant’s unique ID. We store all materials securely on encrypted servers at the coordinating institute, accessible only to authorized staff. We use noScribe, a General Data Protection Regulation (GDPR)-compliant software, to transcribe audio recordings. We tag the transcripts with participant IDs and remove or pseudonymize personal identifiers. Once transcription is complete, we securely delete all audio files and personal contact information. Six months later, our trusted third party contacts the participants who have previously consented to further data collection for the follow-up. Using a virtual team workspace (Atlassian’s Confluence) allows us to effectively store and structure pseudonymized notes and coding in a tabular format, share insights and create visualizations, regardless of the researchers’ location. Data analysis The analysis of the pseudonymized data material, including transcripts and postscripts, is based on Kuckartz’s qualitative content analysis45 using MAXQDA 20/22.46 QInsights47 is used to create case summaries. Depending on the nature of the data, further analysis methods will be applied. We strive for a methodologically controlled approach through practical application of the phases of data analysis described by Kuckartz,45 as well as by validation with respondents and the project team. The management team regularly meet as an interpretation group,48 in person or via a privacy-compliant video­conferencing system. In addition, the patient and relatives’ team also provides support in interpreting the data. Reporting is based on standards for reporting qualitative data.49 In addition, we will continue to work with the IM protocol39 to summarize the results from WP 1 and WP 2. Ethics and dissemination When using the term ‘survivors’ in this article, we are aware that there are a number of reasons why people may not identify with the social label ‘cancer survivor’ or may reject it altogether.50 Such labels serve various functions, including constructing meaning, facilitating acceptance, and shaping perceptions and reactions within the social environment of those affected.51 However, some people have negative associations with the term ‘cancer survivor’ because it may not be inclusive or reflect everyone’s experiences.50,52 The term ‘cancer survivor’ (‘Krebsüberlebende’ in German) is rarely used in German-speaking countries. The most common terms are ‘cancer patient’ or ‘person with cancer’.53 We have primarily used descriptive terms such as ‘people with melanoma’ when addressing (potential) participants. The term ‘survivor’ was only used for publication purposes. Our study received ethical approval from the Institutional Review Board of the University of Magdeburg. Participation is voluntary and can be terminated at any time, even during an interview or a focus group discussion. Nonparticipation or dropping out of the study has no negative consequences for participants. Consent to participate may also be withdrawn at any time without reason or prejudice. We will inform participants about the aims and content of the study, as well as about data protection, when they first express an interest in participating and again before the interview or the focus group discussion. Before participating in the study, all participants will give their written consent. All study activities will be conducted in strict compliance with the GDPR and in accordance with the Declaration of Helsinki.54 Data from interviews and focus groups will be stored pseudonymously. The Institute of Biometry and Medical Informatics (Faculty of Medicine, Otto-von-Guericke-University) stores the consent forms and contact details of the participants for recontacting them, as well as the pseudonymization keys, and manages possible revocations. The topics discussed in the interviews and focus groups should not cause any negative feelings among our participants. However, if difficult situations arise, we will contact the hospital’s internal counselling services, a local crisis intervention team or a support group. Additionally, if researchers encounter difficult situations during interviews, each interviewer will be assigned a contact person from the project team for support. Data will be published primarily as open-source or made available by the corresponding author or principal investigator upon reasonable request. The research consortium will present the results at conferences. Project results will also be published on the LeMela website and through social media in an easily understandable way for stakeholders. Results Work on WP 1 began in January 2025. Recruitment for WP 2 started at the end of March. The final draft of the SCP and the concept for the feasibility and pilot study will be available in March 2026. Discussion To the best of our knowledge, LeMela is the first project to systematically develop and evaluate an SCP for people living with and beyond metastatic melanoma receiving care at skin cancer ­centres. Our project addresses the survivorship care needs of people with metastatic melanoma through a participatory process, guided on theory and grounded in evidence. Kamminga et al. showed in their 2023 study that HCPs see themselves as having a potentially important role in optimizing the SCP and adapting it to the individual needs of patients. They recognize the added value for patients and HCPs, especially by providing an (up-to-date) overview of relevant information about the disease and the (medical) situation of the patients, for example about the schedule of follow-up care.18 Furthermore, a Delphi consensus study revealed the importance of understanding and addressing potential divergences in the perspectives of survivors and HCPs. Exploring and overcoming these differences and incorporating the agreed-upon elements into the design of a melanoma SCP can facilitate its implementation and effectiveness in practice.21 We hope that, through our participatory multistakeholder intervention development process, which involves people living with and beyond melanoma, their relatives and HCPs, combined with a scoping review, we will gain a broader insight into the unmet needs of our target groups and the goals and interventions of the SCP. We will monitor and address any challenge encountered during the research process, such as a lack of stakeholder participation and involvement. In this case, we would revise our recruitment strategy to focus on achieving our goals. Furthermore, we will critically review and discuss our approach and the results during our regular meetings with patient representatives, as well as during our annual meetings with the project advisory board. Although our study focuses on developing an SCP for people living with and beyond metastatic melanoma within the specific healthcare context of Germany, the SCP to be developed may also be applicable to other cancer types and healthcare contexts. As the development of the SCP is based on a participartory ­multistakeholder approach using mixed methods, it can be assumed that the intervention can be adapted internationally. The results of phase A, the design of the SCP, the intervention methods and strategies, the programme organization, the acceptance and implementation planning, and the evaluation planning, form the basis for the feasibility and pilot study (phase B). The pilot study of the developed SCP will start in May 2026. In a pragmatic randomized controlled trial, the feasibility of the SCP will be tested over 12 months at two sites in Germany. Two intervention groups and two control groups are planned. Our evaluation will assess the feasibility of both a randomized controlled trial and of the SCP as an intervention, using a mixed-methods approach. A separate protocol for phase B will also be developed and preregistered.